Alain Kirchmeyer
CEO of Cenexi
Notable Quotes
The whole EBITDA decrease from 11 to 5 signals that our transformation project is on the right track, and it will continue to remain on that track.
Q1 FY 2026 has marked the beginning of a meaningful turnaround. We remain firmly focused on our previous commitment: to deliver a positive EBITDA in Q3 FY 2026.
We have a constant flow of opportunities that we are looking at. What is especially encouraging in the last quarter is that we finalized the validation batches for two products that will move in Q1 into commercial production.
We continue to strive for achieving our short-term goals: a positive EBITDA for Q4 of full year 2025.
We are also gaining good traction from partners in new areas outside of small molecules, such as biologics, plasma fraction, and several difficult-to-make technologies.
Our goal to reach high-teen margins is a mid to long-term goal, and there are a number of actions that we have to take.